ClearFlow Opens New Distribution Center to Service European Market

Elsloo, THE NETHERLANDS – September 28, 2016 — ClearFlow, Inc., a medical device company headquartered in Anaheim, California and with a European office in Amsterdam, has announced the opening of its new dedicated European Service Center near Maastricht, the Netherlands. ClearFlow is the maker of the PleuraFlow® Active Clearance Technology® System, which proactively prevents or … Continued

Read More

ClearFlow Announces New Clinical Study with Positive Results for the PleuraFlow System

Anaheim, CA – November 15, 2016. ClearFlow, Inc., a medical device company based in Anaheim, California has announced the publication of positive results in a clinical trial evaluating the PleuraFlow® Active Clearance Technology® System. Data indicating a marked reduction in Retained Blood Syndrome (RBS) among patients recovering from implantation of left ventricular assist devices (LVAD) … Continued

Read More

ClearFlow Executives Comment on Need for New Protocols

Anaheim, CA – January 31, 2017—Clinical study results presented at the Society of Critical Care Medicine (SCCM) 46th Annual Critical Care Congress in Honolulu last week suggest that all heart surgery patients are at risk for Retained Blood Syndrome, not just high-risk patients, as previously assumed. All patients having heart surgery are required to have … Continued

Read More

Ablexis Announces Perpetual License of the AlivaMab Mouse to Tri-Institutional Therapeutics Discovery Institute

Ablexis Continues Expansion of List of Licensees of AlivaMab Mouse BURLINGAME, Calif., Jan. 12, 2017 (GLOBE NEWSWIRE) — Ablexis, LLC announced today that it has entered into a non-exclusive, perpetual license agreement with the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) in New York City to provide access to the AlivaMab Mouse for antibody drug discovery … Continued

Read More

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and broad rights to use the AlivaMab Mouse for antibody drug discovery and development. … Continued

Read More

Ablexis Announces Perpetual License of the AlivaMab Mouse to a Top 15 Pharma

AlivaMab Mouse Is Next-Generation Antibody Drug Discovery Platform of Choice for Top Pharmas BURLINGAME, Calif.–(BUSINESS WIRE)– Ablexis, LLC announced today the expansion of the roster of licensees of its AlivaMab Mouse technology to include an additional top 15 pharmaceutical company. This perpetual, non-exclusive license provides the licensee with its own colony of AlivaMab Mouse and … Continued

Read More

Spine Wave Announces the Commercial Launch of the True Position® Pivoting Spacer System

SHELTON, CT–(Marketwired – July 11, 2016) – Spine Wave, Inc. is committed to the commercialization of high-quality, innovative medical devices for the treatment of spinal disorders. Spine Wave’s commitment was demonstrated by its previously announced acquisition of rights in the True Position® Pivoting Spacer System from Atlas Spine on February 23, 2016. Since then, Spine … Continued

Read More

AiVita Biomedical Receives FDA Approval for Phase II Ovarian Cancer Treatment

IRVINE, Calif., June 21, 2016 /PRNewswire/ — AiVita Biomedical, a therapeutic development company focused on regenerative and curative medicines, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to begin a Phase II clinical study. The study will investigate the efficacy of AiVita’s novel immunotherapy … Continued

Read More

AiVita Biomedical Raises $2m in Series A Financing for Commercial and Clinical-Stage Program Development

IRVINE, Calif., June 10, 2016 /PRNewswire/ — AiVita Biomedical, a therapeutic development company focused on regenerative and curative medicines, today announced it has completed a $2 million Series A round of equity investment. The capital comes from California Technology Ventures (CTV), a Southern California venture capital firm that focuses its investments in the fields of … Continued

Read More